This brief describes results from an analysis conducted by PATH comparing the current intramuscular version of depot medroxyprogesterone acetate (DMPA) injectable contraceptive compared with a new formulation packaged in the Uniject injection system. The analysis focused on waste management implications, identifying key quantitative and qualitative differences between the two products.

Corporate author(s): PATH

Publication date: February 2011

Available materials


Logistics and Waste Management Benefits of depo-subQ in Uniject

686 KB PDF

Hard copies are not available.

Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.

Related regions: Global

See also:

For more information…

Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA